AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 million upfront to form a new drug discovery pact with Gedeon Richter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,